Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)

被引：1

作者：

Morgans, A. K. ^{[1
]}

Gschwend, J. E. ^{[2
]}

Shore, N. D. ^{[3
]}

Ross, A. ^{[4
]}

Feng, F. ^{[5
]}

Hope, T. ^{[6
]}

Trandafir, L. ^{[7
]}

Le Berre, M-A. ^{[8
]}

Kuss, I. ^{[9
]}

Joensuu, H. ^{[10
]}

Fizazi, K. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Med Dept, Boston, MA USA

[2] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany

[3] GenesisCare US, Uro Oncol Dept, Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Northwestern Univ, Urol, Feinberg Sch Med, Chicago, IL USA

[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Radiat Oncol, San Francisco, CA USA

[6] Univ Calif San Francisco, Radiol Sch Med, San Francisco, CA USA

[7] Bayer Consumer Care AG, R&D Dept, Basel, Switzerland

[8] Bayer Healthcare France, Biometry, Loos, France

[9] Bayer AG, Clin Dev SBU Oncol, Berlin, Germany

[10] Orion Corp, Orion Pharma, Espoo, Finland

[11] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2789

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

184TiP

引用

页码：S997 / S998

页数：2

共 50 条

[31] Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 17 - 18
[32] A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
Horti, Jozsef
Widmark, Anders
Stenzl, Arnulf
Federico, Miriam H.
Abratt, Raymond P.
Sanders, Nick
Pover, Gillian M.
Bodrogi, Istvan
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (02) : 175 - 180
[33] Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
Sternberg, Cora
Armstrong, Andrew
Pili, Roberto
Ng, Siobhan
Huddart, Robert
Agarwal, Neeraj
Khvorostenko, Denis
Lyulko, Olexiy
Brize, Arija
Vogelzang, Nicholas
Delva, Remy
Harza, Mihai
Thanos, Anastasios
James, Nicholas
Werbrouck, Patrick
Boegemann, Martin
Hutson, Thomas
Milecki, Piotr
Chowdhury, Simon
Gallardo, Enrique
Schwartsmann, Gilberto
Pouget, Jean-Christophe
Baton, Frederique
Nederman, Thore
Tuvesson, Helen
Carducci, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2636 - U136
[34] A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer
Hille, A
Schmidberger, H
Hermann, RM
Christiansen, H
Saile, B
Pradier, O
Hess, CF
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (05): : 1488 - 1493
[35] Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Brighton, Timothy A.
Khot, Amit
Harrison, Simon J.
Ghez, David
Weiss, Brendan M.
Kirsch, Andres
Magen, Hila
Gironella, Mercedes
Oriol, Albert
Streetly, Matthew
Kranenburg, Britte
Qin, Xiang
Bandekar, Rajesh
Hu, Peter
Guilfoyle, Mary
Qi, Ming
Nemat, Sepideh
Goldschmidt, Hartmut
CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3772 - 3775
[36] Dietary intervention in prostate cancer patients:: PSA response in a randomized double-blind placebo-controlled study
Kranse, R
Dagnelie, PC
van Kemenade, MC
de Jong, FH
Blom, JHM
Tijburg, LBM
Weststrate, JA
Schröder, FH
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (05) : 835 - 840
[37] Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC).
Fizazi, Karim
Larsen, Julie S.
Matheny, Shannon
Molina, Arturo
Li, Jinhui
Todd, Mary Beth
Yu, Margaret K.
Kheoh, Thian San
Namphuong Tran
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Roche Kapoor
Matthew P. Deek
Riley McIntyre
Natasha Raman
Megan Kummerlowe
Iyah Chen
Matt Gaver
Hao Wang
Sam Denmeade
Tamara Lotan
Channing Paller
Mark Markowski
Michael Carducci
Mario Eisenberger
Tomasz M. Beer
Daniel Y. Song
Theodore L. DeWeese
Jason W. Hearn
Stephen Greco
Curtiland DeVille
Neil B. Desai
Elisabeth I. Heath
Stanley Liauw
Daniel E. Spratt
Arthur Y. Hung
Emmanuel S. Antonarakis
Phuoc T. Tran
BMC Cancer, 19
[39] Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
Rugo, Hope S.
Stopeck, Alison T.
Joy, Anil A.
Chan, Stephen
Verma, Shailendra
Lluch, Anna
Liau, Katherine F.
Kim, Sinil
Bycott, Paul
Rosbrook, Brad
Bair, Angel H.
Soulieres, Denis
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2459 - 2465
[40] A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Kapoor, Roche
Deek, Matthew P.
McIntyre, Riley
Raman, Natasha
Kummerlowe, Megan
Chen, Iyah
Gaver, Matt
Wang, Hao
Denmeade, Sam
Lotan, Tamara
Paller, Channing
Markowski, Mark
Carducci, Michael
Eisenberger, Mario
Beer, Tomasz M.
Song, Daniel Y.
DeWeese, Theodore L.
Hearn, Jason W.
Greco, Stephen
DeVille, Curtiland
Desai, Neil B.
Heath, Elisabeth I.
Liauw, Stanley
Spratt, Daniel E.
Hung, Arthur Y.
Antonarakis, Emmanuel S.
Tran, Phuoc T.
BMC CANCER, 2019, 19 (1)

← 1 2 3 4 5 →